Theravance Biopharma (NASDAQ:TBPH) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a strong-buy rating to a buy rating in a research report released on Saturday morning.

TBPH has been the subject of a number of other reports. HC Wainwright lifted their price target on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Finally, B. Riley began coverage on Theravance Biopharma in a research note on Friday, September 12th. They set a “buy” rating and a $28.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $24.25.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $17.39 on Friday. The stock’s fifty day moving average is $14.55 and its 200 day moving average is $12.35. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $18.96. The firm has a market capitalization of $881.15 million, a PE ratio of 30.51 and a beta of 0.07.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership acquired a new stake in Theravance Biopharma in the third quarter valued at approximately $10,611,000. Assenagon Asset Management S.A. lifted its position in shares of Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares in the last quarter. Nuveen LLC acquired a new stake in Theravance Biopharma in the 1st quarter valued at $3,348,000. Hillsdale Investment Management Inc. purchased a new stake in Theravance Biopharma in the 3rd quarter worth $4,536,000. Finally, Jefferies Financial Group Inc. increased its stake in shares of Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock worth $3,054,000 after purchasing an additional 255,455 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.